Biotech/Medical Tech Stock News from Investorideas.com
Biotech, Pharma and Medical Technology Stock News : OTC stocks, TSX Stocks, NASDAQ and NYSE
Investorideas.com newswire, breaking biotechnology and pharma news
Friday, March 15, 2024
Biopharma Stock News Bite - Geron Corporation (Nasdaq: GERN) Makes NASDAQ Top Gainers List on FDA News
Wednesday, March 13, 2024
Biotech Stock News Bite - Heron Therapeutics, Inc. (Nasdaq: HRTX) Higher on Fourth Quarter and Full-Year 2023 Financial Results
Tuesday, March 12, 2024
Biotech Stock News Bite - Regulus Therapeutics Inc. (Nasdaq: RGLS) Makes NASDAQ Top Ten Gainers List
Monday, March 11, 2024
Watching Biotech & Life Science Stocks: (Nasdaq: $IXHL) (Nasdaq: $ATRA) (ASX: $CHM.AX)(Nasdaq: $IMRX)
Watching Biotech & Life Science Stocks: (Nasdaq: $IXHL) (Nasdaq: $ATRA) (ASX: $CHM.AX)(Nasdaq: $IMRX)
Transportation Stocks on the Move: (Nasdaq: $DUOT) (Nasdaq: $RVSN) (NYSE: $ASC)
March 11, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech and Transportation sectors.
Read this in full at https://www.investorideas.com/news/2024/main/03111Stocks.asp
The newest biotech companies focus on cancer treatments and medical cannabis and psychedelic medicine uses.
The latest transportation companies provide transportation include a tanker company and rail safety companies using AI (artificial intelligence) technology.
New Stocks Added to the Biotech Directories:
Incannex Healthcare Inc. (Nasdaq: IXHL) is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
Atara Biotherapeutics (Nasdaq: ATRA) is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases.
Chimeric Therapeutics (ASX: CHM) a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.
Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor currently in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor and will be evaluated in a Phase 1/2a study in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs.
New Stocks Added to the Transportation Directories:
Ardmore Shipping (NYSE:ASC) owns and operates a fleet of MR product and chemical tankers ranging from 25,000 to 50,000 deadweight tonnes. Ardmore provides, through its modern, fuel-efficient fleet of mid-size tankers, seaborne transportation of petroleum products and chemicals worldwide to oil majors, national oil companies, oil and chemical traders, and chemical companies. Ardmore's core strategy is to continue to develop a modern, high-quality fleet of product and chemical tankers, build key long-term commercial relationships and maintain its cost advantage in assets, operations and overhead, while creating synergies and economies of scale as the company grows. Ardmore provides its services to customers through voyage charters and time charters, and enjoys close working relationships with key commercial and technical management partners. Ardmore's Energy Transition Plan ("ETP") focusses on three key areas: transition technologies, transition projects, and sustainable (non-fossil fuel) cargos. The ETP is an extension of Ardmore's strategy, building on its core strengths of tanker chartering, shipping operations, technical and operational fuel efficiency improvements, technical management, construction supervision, project management, investment analysis, and ship finance.
Duos Technologies Group (Nasdaq:DUOT) based in Jacksonville, Florida, through its wholly owned subsidiary, Duos Technologies, Inc., designs, develops, deploys and operates intelligent vision-based technology solutions using Machine Vision and Artificial Intelligence (“AI”) to analyze fast moving freight, passenger and transit trains and trucks streamlining operations, improving safety and reducing costs. The Company provides cutting edge solutions that automate the mechanical and security inspection of fast-moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence.
Rail Vision Ltd. (Nasdaq: RVSN) is a technology company that is seeking to revolutionize railway safety and the data-related market. The Company has developed cutting-edge, artificial intelligence-based, industry-leading technology specifically designed for railways. The Company has developed its railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operators. Rail Vision believes that its technology will significantly increase railway safety around the world, while creating significant benefits and adding value to everyone who relies on the train ecosystem: from passengers using trains for transportation to companies that use railways to deliver goods and services. In addition, the company believes that its technology has the potential to advance the revolutionary concept of autonomous trains into a practical reality.
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
Read the recent AI Transportation article at:
https://www.investorideas.com/news/2024/technology/03041AI-Stocks.asp
Read the recent Biotech/Oncology Article at:
https://www.investorideas.com/news/2024/biotech/03061Pancreatic-Cancer-Market-Stocks.asp
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Learn more about advertising and guest posts
https://www.investorideas.com/Advertise/
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com to be added to our stock directories or learn more about us
Dawn Van Zant and Cali Van Zant
800 665 0411
Wednesday, March 6, 2024
Cancer/Oncology Stocks to Watch; (Nasdaq: $GLSI) (NYSE American: $CLDI) (Nasdaq: $FUSN) (NASDAQ: $ACHL)
Cancer/Oncology Stocks to Watch; (Nasdaq: $GLSI) (NYSE American: $CLDI) (Nasdaq: $FUSN) (NASDAQ: $ACHL)
Focus on Biotech Stocks: (Nasdaq: $GUTS) (NYSE: $ANRO) (Nasdaq: $KYTX) (Nasdaq: $BYSI)
March 6, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech sector.
Read this in full at https://www.investorideas.com/news/2024/main/03061Stocks.asp
The newest biotech companies are focused on cancer treatment, oncology, metabolic therapeutics, autoimmune diseases and neurobiology.
New Stocks Added to the Biotech Directories:
Fractyl Health, Inc. (Nasdaq:GUTS) is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including T2D and obesity. Despite advances in treatment over the last 50 years, T2D and obesity continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Lexington, MA.
Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions.
Kyverna Therapeutics, Inc. (Nasdaq:KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.
Greenwich LifeSciences, Inc. (Nasdaq:GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, Flamingo-01.
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 clinical trial; and FPI-2059, a small molecule targeting neurotensin receptor 1, currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors and immuno-oncology agents. The Company received IND clearance for FPI-2068, the first novel TAT under the collaboration, which targets EGFR-cMET. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion has a Good Manufacturing Practice compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs. The Company has signed strategic actinium supply agreements with Niowave, Inc. and BWXT Medical.
Achilles Therapeutics Plc ADR (NASDAQ:ACHL) is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
BeyondSpring Inc. (Nasdaq:BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly.
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
Research more biotech stocks with Investorideas Biotech stock directory
https://www.investorideas.com/BIS/Stock_List.asp
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Learn more about advertising and guest posts
https://www.investorideas.com/Advertise/
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com to be added to our stock directories or learn more about us
Dawn Van Zant and Cali Van Zant
800 665 0411
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market (NASDAQ: $ONCY) (TSX: $ONC.TO) (NASDAQ: $BLRX) (NASDAQ: $IMRX) (NASDAQ: $CADL) @Oncolytics @BioLineRx_Ltd @Immuneering @CandelTx
Biotech/Oncology Stocks
Targeting the Pancreatic Cancer Market (NASDAQ: $ONCY) (TSX: $ONC.TO) (NASDAQ: $BLRX)
(NASDAQ: $IMRX) (NASDAQ: $CADL) @Oncolytics @BioLineRx_Ltd @Immuneering
@CandelTx
A Race worth Winning
March 6,
2024 - Investorideas.com, a global investor news source covering
biotech and pharma stocks issues a sector snapshot on developments for
pancreatic cancer treatments, featuring Oncolytics
Biotech® Inc. (NASDAQ:
ONCY) (TSX:
ONC), a clinical-stage immunotherapeutics
company focused on oncology.
Read this article,
featuring ONCY in full at: https://www.investorideas.com/news/2024/biotech/03061Pancreatic-Cancer-Market-Stocks.asp
Research
Nester says, “The global pancreatic
cancer market size is slated to expand at ~18% CAGR between 2024 and 2036. The
market is poised to garner a revenue of USD 36 billion by the end of 2036, up
from a revenue of ~USD 6 billion in the year 2023. The incidence of pancreatic
cancer is increasing globally, which is driving the growth of the market.”
The American Cancer
Society’s estimates for pancreatic cancer in the United States
for 2024 are: “About 66,440 people (34,530 men and 31,910 women) will be
diagnosed with pancreatic cancer. About 51,750 people (27,270 men and 24,480
women) will die of pancreatic cancer. Pancreatic cancer accounts for about 3%
of all cancers in the US and about 7% of all cancer deaths.”
Biotech/oncology stocks targeting the
growing global pancreatic cancer market have made headlines with recent
developments and breakthroughs in treatments.
Oncolytics Biotech® Inc. (NASDAQ:
ONCY) (TSX:
ONC), a clinical-stage immunotherapeutics
company focused on oncology just
announced it has submitted an amendment to
GOBLET to initiate a new Phase 1/2 cohort evaluating pelareorep in combination
with modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab (Tecentriq®)
in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma
(PDAC). This amendment will be reviewed by the Paul Ehrlich Institute (PEI;
Germany’s regulatory body) for approval before patient enrollment can begin.
The cohort, the fifth of the GOBLET gastrointestinal cancer study, is being
supported by the US$5 million Therapeutic Accelerator Award from the Pancreatic
Cancer Action Network (PanCAN), an innovative program established to accelerate
the development of new treatments for pancreatic cancer.
“We are enthusiastic to have the support of
PanCAN to expand the evaluation of pelareorep in pancreatic cancer and explore
mFOLFIRINOX as another combination that could improve outcomes for patients.
Notably, this patient population is newly diagnosed patients who are receiving
first-line treatment. Chemotherapies, including either mFOLFIRINOX or
gemcitabine and nab-paclitaxel, are the backbone treatment regimens of
pancreatic cancer therapy1. Evaluating pelareorep in combination
with these widely used regimens is an important step in our broad clinical
development program,” said Dr. Matt Coffey, President and Chief Executive
Officer of Oncolytics. “Last fall, we reported a 62% objective response rate
for the GOBLET PDAC cohort studying pelareorep in combination with the
checkpoint inhibitor atezolizumab in addition to gemcitabine and nab-paclitaxel
(link
to the PR, link
to the poster). This response is about
three times that of historical controls and forms the basis of the
registrational program, expected to begin this year. Therefore, we are
enthusiastic about this new mFOLFIRINOX pancreatic cancer cohort and look
forward to enrolling the first patient as soon as possible.”
Dirk Arnold, M.D., Ph.D., Director of
Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial
commented, “One of the reasons for pancreatic cancer’s poor survival rate is
that it effectively evades the immune system and can induce an
immunosuppressive tumor microenvironment (TME)2. Pelareorep is an
attractive combination partner because of its ability to address both issues by
activating the innate and adaptive immune systems while driving the remodeling
of the tumor microenvironment. Positive results from the Phase 2 study
evaluating pelareorep combined with atezolizumab and chemotherapy reported last
fall support the potential use of these agents together. I am hopeful that the
combination of pelareorep and mFOLFIRINOX (with or without atezolizumab) will
yield positive response data and advance the development of new treatment
options for patients with pancreatic cancer.”
“This study is designed to evaluate whether
pelareorep can enhance outcomes in patients receiving mFOLFIRINOX, one of the
most commonly used metastatic pancreatic cancer treatments. Combining
pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic
cancer program and maximizes the potential of pelareorep-based combination
therapies to benefit pancreatic cancer patients,” commented Thomas Heineman,
M.D., Ph.D., Chief Medical Officer at Oncolytics. “The mFOLFIRINOX cohort
utilizes a screened selection design within a Simon two-stage approach that will also allow evaluation of the
contribution of atezolizumab to the pelareorep/mFOLFIRINOX combination. In
addition, this study is designed to provide valuable translational assessments,
such as the expansion of tumor-infiltrating lymphocytes (TILs) in the blood,
which has been associated with tumor responses. We look forward to building on
PanCAN’s strong relationships with the pancreatic cancer community and
furthering our collaboration with AIO-Studien-gGmbH
(AIO) on the GOBLET study.”
BioLineRx
Ltd. (NASDAQ: BLRX), a commercial stage biopharmaceutical
company pursuing life-changing therapies in oncology and rare diseases recently announced that the first patient has been dosed in the
randomized CheMo4METPANC Phase 2 combination clinical trial evaluating the
company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and
standard of care chemotherapies gemcitabine and nab-paclitaxel, versus
gemcitabine and nab-paclitaxel alone, in first-line PDAC. The
investigator-initiated trial is being conducted in collaboration with Columbia
University and is the first large, multi-center, randomized study evaluating
motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies.
"Pancreatic
ductal adenocarcinoma (PDAC) has had limited responses to traditional
immunotherapy, resulting in a poor prognosis for patients and an urgent need
for new treatment approaches," said Philip Serlin, Chief Executive Officer
of BioLineRx. "We are encouraged by our early pilot data and look forward
to continuing to advance the expanded, randomized Phase 2 CheMo4METPANC trial
for patients living with this cancer."
From the news: Findings from the single-arm pilot phase of
the CheMo4METPANC trial were shared by Dr. Gulam Manji, MD, PhD, of Columbia
University at the 10th Annual Immuno-Oncology (IO) 360° Summit in Brooklyn, New
York on Thursday, February 29, 2024. The findings were previously presented
during an oral presentation at the American Association of Cancer Research
(AACR) Special Conference on Pancreatic Cancer in Boston, Massachusetts,
September 28, 2023. As of July 2023, 7 of the 11 patients (64%) in the pilot
phase experienced a partial response (PR) of which 5 (45%) were confirmed PRs
at the time of the data cut; one patient experienced resolution of the hepatic
(liver) metastatic lesion; and three patients (27%) experienced stable disease,
resulting in a disease control rate of 91%.
From the news: Motixafortide, BioLineRx's lead therapeutic
candidate, was approved by the U.S. Food & Drug Administration (FDA) in
September 2023, in combination with filgrastim (G-CSF), to mobilize
hematopoietic stem cells for collection and subsequent autologous
transplantation in patients with multiple myeloma, under the brand name
APHEXDA®. Motixafortide is also being evaluated in a Phase 1 clinical trial
evaluating motixafortide as a monotherapy and in combination with natalizumab
for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in
sickle cell disease (SCD).
Immuneering
Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking
to develop and commercialize universal-RAS/RAF medicines for broad populations
of cancer patients announced in February that the FDA granted Fast Track designation
for its lead clinical-stage program, IMM-1-104, for the treatment of patients
with PDAC who have failed one line of treatment. IMM-1-104 is designed to
provide universal-RAS activity through deep cyclic inhibition of the MAPK
pathway with once-daily oral dosing.
“We welcome
FDA’s decision to grant Fast Track designation for IMM-1-104. Our Phase 1/2a
study is designed to evaluate IMM-1-104 in pancreatic cancer, as well as a
number of other tumor types associated with the RAS pathway. We look forward to
a data-rich 2024 as we plan to provide multiple readouts from our study this
year,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of
Immuneering.
From the news: Vincent Chung, M.D., FACP, Professor,
Department of Medical Oncology and Therapeutics Research, is the principal
investigator of the Phase 1/2a clinical study with IMM-1-104 at City of Hope,
one of the largest cancer research and treatment organizations in the United
States.
“The FDA’s
decision reinforces the importance of developing effective, novel treatments to
improve the health outcomes of patients with pancreatic ductal adenocarcinoma.
The development of well-tolerated oral medicines would improve the lives of
these patients. City of Hope offers many clinical trials testing innovative
treatments for people with pancreatic cancer," Chung said.
Candel Therapeutics, Inc.(Nasdaq: CADL), a clinical stage biopharmaceutical company
focused on developing multimodal biological immunotherapies to help patients
fight cancer, previously announced that the FDA granted Fast Track Designation
for its lead investigational adenovirus asset CAN-2409 plus prodrug
(valacyclovir) for the treatment of patients with PDAC to improve overall
survival.
“We are pleased with the FDA's decision to grant Fast Track
Designation for CAN-2409 in pancreatic cancer,” said Paul Peter Tak, MD, PhD,
FMedSci, President and CEO of Candel. “This milestone follows our first interim
data report from the randomized phase 2 clinical trial in patients with
borderline resectable PDAC that showed prolonged and sustained survival after
experimental treatment with CAN-2409, especially when compared to real-world
data on patients receiving radiotherapy treatment. Candel remains on track to
release updated overall survival data from the interim analysis of this clinical
trial in the second quarter of 2024. We are grateful to the patients,
caregivers, investigators and clinical sites that have taken part in this
clinical trial.”
With lives at stake and market opportunity in front of
them, the race is on for companies aiming to fast track solutions for
pancreatic cancer. It’s a race worth winning!
References
1.
Botta G, et al. SWI/SNF
complex alterations as a biomarker of immunotherapy efficacy in pancreatic
cancer. JCI Insight. 2021;6(18):e150453. https://doi.org/10.1172/jci.insight.150453.
2.
Yoon JH, et al.
Immunotherapy for pancreatic cancer. World J Clin Cases. 2021 May
6;9(13):2969-2982. doi: 10.12998/wjcc.v9.i13.2969. PMID: 33969083; PMCID:
PMC8080736.
Research more biotech stocks with Investorideas Biotech
stock directory
https://www.investorideas.com/BIS/Stock_List.asp
About Investorideas.com - Big
Investing Ideas
Investorideas.com is the go-to platform for big
investing ideas. From breaking stock news to top-rated investing podcasts, we
cover it all. Our original branded content includes podcasts such as Exploring
Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create
free investor stock directories for sectors including mining, crypto, renewable
energy, gaming, biotech, tech, sports and more. Public companies within the
sectors we cover can use our news publishing and content creation services to
help tell their story to interested investors. Paid content is always
disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
management and IR of each company directly regarding specific questions. Disclosure:
This article featuring Oncolytics Biotech Inc. is a paid for article at InvestorIdeas.com. More disclaimer
info: https://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country. Please
read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Twitter @investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
Biotech Industry Stocks- investing ideas in biotechnology
stocks, medical technology and life sciences
Like Biotech Stocks? View our Biotech
Stocks Directory
Get News Alerts on Biotech Stocks
Tuesday, March 5, 2024
Increasing Incidence Of Pancreatic Cancer Leading To A $6.85 Billion Dollar Market Size For New Treatments; @FNMgroup @Oncolytics
Increasing
Incidence Of Pancreatic Cancer Leading To A $6.85 Billion Dollar Market Size
For New Treatments; @FNMgroup @Oncolytics
Palm
Beach, FL – March 5, 2024 – FN Media Group News
Commentary – Pancreatic cancer is one of the leading causes of
cancer death globally. The increasing incidence of this cancer across the U.S.
and other parts of the world is one of the factors driving the need for the
drugs used in the treatment. Moreover, the prevalence is significantly higher
in the geriatric population compared to other types of cancers. Thus, an
increase in the geriatric population is one factor driving the pancreatic
cancer treatment market growth. The incidence is significantly higher in the geriatric
population above 65 years of age compared to other types of cancers. A report from
Fortune Business Insights said that: “the pancreatic cancer treatment market
size is projected to grow to USD 6.85 billion by 2029, exhibiting a CAGR of
15.7% during 2022-2029. North America dominated the global market with a share
of 46.97% in 2022. The increase in the number of patients suffering from the
condition has increased the demand for the drugs used in treatment. These are
some factors driving the growth during the forecast period. Companies
engaged in manufacturing cancer drugs have increased their focus on R&D
activities to develop new drugs for pancreatic cancer treatment. Additionally,
the companies operating in the market have received approval from several
regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the
Medicines and Healthcare Products Regulatory Agency (MHRA) (U.K.), among others,
thereby propelling the growth of the market. Moreover, new testing technologies
are being adopted by hospitals and diagnostic centers to diagnose cancer. The
increase in the diagnosis rates is driving the demand for drugs, thereby
providing opportunities for the players.” Active biotech and pharma
companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQ:
ONCY) (TSX: ONC), Ocean Biomedical, Inc. (NASDAQ: OCEA), LAVA
Therapeutics N.V. (NASDAQ: LVTX), Merck
& Co., Inc. (NYSE: MRK), AbbVie
Inc. (NYSE: ABBV).
Read this in full at https://www.financialnewsmedia.com/increasing-incidence-of-pancreatic-cancer-leading-to-a-6-85-billion-dollar-market-size-for-new-treatments/
Fortune Business Insights continued: “Shifting the focus of key
players in extensive R&D activities to develop new drugs and an increase in
funding for cancer research led to the development of new drugs for treatment.
Additionally, several pharmaceutical companies are involved in clinical trials
to develop new drugs and explore the potential of the molecule to treat the
disease. Thus, with the increased funding for R&D activities,
companies are focused on developing new drugs, thereby contributing to the
overall rise in demand for drugs for pancreatic type of cancer treatment. Thus,
increasing aging population and rising government initiatives to create
awareness for the diagnosis of the condition are some factors propelling the
market growth.”
Oncolytics Biotech® Inc. (NASDAQ:
ONCY) (TSX: ONC) Files Amendment to Initiate New Pancreatic Cancer GOBLET
Cohort Supported by PanCAN – US$5M grant supports study of
pelareorep in combination with modified FOLFIRINOX +/- atezolizumab – Oncolytics
Biotech® Inc., a clinical-stage immunotherapeutics company focused on oncology,
today announced it has submitted an amendment to GOBLET to initiate a new Phase
1/2 cohort evaluating pelareorep in combination with modified FOLFIRINOX
(mFOLFIRINOX) with and without atezolizumab (Tecentriq®) in patients with newly
diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). This amendment
will be reviewed by the Paul Ehrlich Institute (PEI; Germany’s regulatory body)
for approval before patient enrollment can begin. The cohort, the fifth of the
GOBLET gastrointestinal cancer study, is being supported by the US$5 million
Therapeutic Accelerator Award from the Pancreatic Cancer Action Network
(PanCAN), an innovative program established to accelerate the development of
new treatments for pancreatic cancer.
“We are enthusiastic to have the support of PanCAN to expand the
evaluation of pelareorep in pancreatic cancer and explore mFOLFIRINOX as
another combination that could improve outcomes for patients. Notably, this
patient population is newly diagnosed patients who are receiving first-line
treatment. Chemotherapies, including either mFOLFIRINOX or gemcitabine and
nab-paclitaxel, are the backbone treatment regimens of pancreatic cancer
therapy. Evaluating pelareorep in combination with these widely used regimens
is an important step in our broad clinical development program,” said Dr. Matt
Coffey, President and Chief Executive Officer of Oncolytics. “Last fall, we
reported a 62% objective response rate for the GOBLET PDAC cohort studying
pelareorep in combination with the checkpoint inhibitor atezolizumab in addition
to gemcitabine and nab-paclitaxel (link to the PR, link to the poster).
This response is about three times that of historical controls and forms the
basis of the registrational program, expected to begin this year. Therefore, we
are enthusiastic about this new mFOLFIRINOX pancreatic cancer cohort and look
forward to enrolling the first patient as soon as possible.”
Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum
Hamburg, and primary investigator of the GOBLET trial, commented, “One of the
reasons for pancreatic cancer’s poor survival rate is that it effectively
evades the immune system and can induce an immunosuppressive tumor
microenvironment (TME). Pelareorep is an attractive combination partner because
of its ability to address both issues by activating the innate and adaptive
immune systems while driving the remodeling of the tumor microenvironment.
Positive results from the Phase 2 study evaluating pelareorep combined with
atezolizumab and chemotherapy reported last fall support the potential use of
these agents together. I am hopeful that the combination of pelareorep and
mFOLFIRINOX (with or without atezolizumab) will yield positive response data
and advance the development of new treatment options for patients with
pancreatic cancer.”
“This study is designed to evaluate whether pelareorep can
enhance outcomes in patients receiving mFOLFIRINOX, one of the most commonly
used metastatic pancreatic cancer treatments. Combining pelareorep with
mFOLFIRINOX represents an expansion of our existing pancreatic cancer program
and maximizes the potential of pelareorep-based combination therapies to
benefit pancreatic cancer patients,” commented Thomas Heineman, M.D., Ph.D.,
Chief Medical Officer at Oncolytics. “The mFOLFIRINOX cohort utilizes a
screened selection design within a Simon two-stage approach that will also
allow evaluation of the contribution of atezolizumab to the
pelareorep/mFOLFIRINOX combination. In addition, this study is designed to
provide valuable translational assessments, such as the expansion of
tumor-infiltrating lymphocytes (TILs) in the blood, which has been associated
with tumor responses. We look forward to building on PanCAN’s strong
relationships with the pancreatic cancer community and furthering our collaboration
with AIO-Studien-gGmbH (AIO) on the GOBLET study.” CONTINUED… Read
these full press releases and more news for ONCY at: https://www.financialnewsmedia.com/news-oncy/
Other recent developments in
the biotech industry of note for cancer events include:
Ocean Biomedical, Inc.
(NASDAQ: OCEA), a biopharma company which endeavors
to accelerate the development of compelling discoveries from top research
scientists, recently congratulated its joint venture partner,
Virion Therapeutics, LLC, a clinical-stage biotechnology company
developing T cell-based immunotherapies, for the acceptance of their
abstract highlighting the first-ever human data from its novel checkpoint
modifier immunotherapy for HBV functional cure, for late breaker oral
presentation at the upcoming 33rd Annual Meeting of
APASL (The Asian Pacific Association for the Study of the Liver), taking
place in Kyoto, Japan from March 27-31, 2024.
The late breaker presentation will highlight the safety data
observed, to date, in the ongoing Phase 1B clinical trial of VRON-0200. “This
accepted abstract highlights Virion’s commitment to finding a functional cure
for chronically HBV-infected patients – and the first-ever human data for a
genetically encoded checkpoint modifier T cell vaccine of any kind. VRON-0200
is uniquely developed to stimulate a patient’s own immune response to the
virus. Additionally, its mechanism of action and intramuscular administration
were designed to limit safety issues for this novel therapy,” said Dr. Sue
Currie, COO of Virion, and one of the study authors. “We look forward to
sharing these late breaking clinical HBV data at APASL, one of the leading
meetings on the treatment of liver diseases in the world.”
LAVA Therapeutics
N.V. (NASDAQ: LVTX), recently announced that
it has entered into a clinical trial collaboration and supply agreement with Merck
& Co., Inc. (NYSE: MRK), Rahway,
NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in
combination with LAVA-1207, a Gammabody® designed to
target the prostate-specific membrane antigen (PSMA) to trigger the potent and
preferential killing of PSMA-positive tumor cells, in patients with therapy
refractory metastatic castration-resistant prostate cancer (mCRPC).
Under the terms of the agreement, Merck & Co., Inc., Rahway,
NJ, USA will provide pembrolizumab for the dose escalation and expansion phases
of LAVA’s ongoing Phase 1/2a study of LAVA-1207 (NCT05369000), with
the combination arm expected to be initiated in the first half of 2024.
Enrollment and dose escalation will also continue in the LAVA-1207 monotherapy
and interleukin-2 arms of the study.
“We are excited to work with Merck & Co., Inc., Rahway, NJ,
USA as we continue to unlock the therapeutic potential of LAVA-1207 and explore
its potential capabilities in combination with KEYTRUDA®,” said Stephen Hurly,
President and Chief Executive Officer, LAVA. “To date, LAVA-1207 has demonstrated
a favorable safety profile and shown preliminary signs of anti-tumor activity.
Prostate cancer has presented challenges for immune checkpoint therapies in the
past – we are hopeful the combination of our products may deliver important
clinical outcomes.”
AbbVie Inc. (NYSE: ABBV) and
OSE Immunotherapeutics SA, a clinical-stage immunotherapy
company, recently announced a
strategic partnership to develop OSE-230, a monoclonal antibody designed to
resolve chronic and severe inflammation, currently in the pre-clinical
development stage.
OSE-230 is a first-in-class monoclonal antibody designed to
activate ChemR23, a G-Protein Coupled Receptor (GPCR) target. Activation
of ChemR23 may offer a novel mechanism for the resolution of chronic
inflammation, modulating functions of both macrophages and neutrophils.
“This collaboration underscores our commitment to expanding our
immunology portfolio with the ultimate goal of improving the standard of care
for patients living with inflammatory diseases globally,” said Jonathon
Sedgwick, Ph.D., senior vice president and global head of discovery research,
AbbVie. “By leveraging our expertise in immunology drug development, we
look forward to advancing OSE-230, which offers a novel mechanism-of-action to
treat chronic inflammation.”
“We are very pleased to collaborate with AbbVie, a global leader
in the development and commercialization of innovative medicines, to drive our
OSE-230 program forward,” said Nicolas Poirier, chief executive officer,
OSE Immunotherapeutics. “This partnership represents a major milestone in our
company’s progress and recognizes the value of our innovative R&D
capabilities. I would like to thank all our employees who helped us reach this
milestone through dedication and hard work.”
About FN Media Group:
At FN Media Group, via our top-rated online news portal at
www.financialnewsmedia.com, we are one of the very few select firms providing
top tier one syndicated news distribution, targeted ticker tag press releases
and stock market news coverage for today’s emerging companies.
Follow us on Facebook to
receive emerging news updates: https://www.facebook.com/financialnewsmedia
Follow us on Twitter for real
time Breaking News: https://twitter.com/FNMgroup
Follow and us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/
DISCLAIMER: FN Media Group LLC (FNM), which owns and
operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party
publisher and news dissemination service provider, which disseminates
electronic information through multiple online media channels. FNM is NOT
affiliated in any manner with any company mentioned herein. FNM and its
affiliated companies are a news dissemination solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNM’s market
updates, news alerts and corporate profiles are NOT a solicitation or
recommendation to buy, sell or hold securities. The material in this
release is intended to be strictly informational and is NEVER to be construed
or interpreted as research material. All readers are strongly urged to
perform research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content and details
which were previously disseminated by the companies mentioned in this
release. FNM is not liable for any investment decisions by its readers or
subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks. For current services
performed FNM was compensated forty nine hundred dollars for news coverage of
the current press releases issued by Oncolytics Biotech® Inc.
by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY
NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E the Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. “Forward-looking statements” describe
future expectations, plans, results, or strategies and are generally preceded by
words such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”. You are
cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors, and
other risks identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements
included herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date hereof and
FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
SOURCE: FN Media Group